Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

Apr 19 2019

• By Mandy Jackson

dna-concept

Related Content

Value Unlocked: BMS Buying Padlock For Up To $600m

Mar 24 2016

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Jan 21 2019

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Dec 07 2017

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Feb 27 2017

'Welcome home': Stromedix buy brings fibrosis drug back to Biogen

Feb 16 2012

Related Companies

Arrakis Therapeutics

Obsidian Therapeutics, Inc.

Sigilon Therapeutics, Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Stromedix, Inc.

Expansion Therapeutics, Inc.

Skyhawk Therapeutics, Inc.

Additional Topics

Financing StartUps and SMEs Business Strategies Commercial Companies BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window